Results 11 to 20 of about 27,758 (263)

Drugging MYCN oncogenic signalling through the MYCN-PA2G4 binding interface [PDF]

Cancer Research, 2019
MYCN is a major driver for the childhood cancer, neuroblastoma, however, there are no inhibitors of this target. Enhanced MYCN protein stability is a key component of MYCN oncogenesis and is maintained by multiple feedforward expression loops involving ...
Zhu, Shizhen, Doughty, Larissa, Gustafson, W Clay, Massudi, Hassina, McCarroll, Joshua A, Norris, Murray D, Koach, Jessica, Marshall, Glenn M, Haber, Michelle, Liu, Bing, Keenan, Bryce, Carter, Daniel R, Gifford, Andrew J, Milazzo, Giorgio, Perini, Giovanni, Holien, Jessica K, Herath, Mika, Stevenson, Brendan W, Oberthuer, Andre, Zhang, Xiaoling, Mayoh, Chelsea, Bell, Jessica L, Gorman, Michael A, Seneviratne, Janith A, Murray, Jayne E, Lim, Taylor, Fischer, Matthias, Parker, Michael W, Hüttelmaier, Stefan, Cheung, Belamy B, Ciampa, Olivia C, Liu, Tao, Fletcher, Jamie I   +32 more
core   +8 more sources

Neuroblastoma and MYCN [PDF]

Cold Spring Harbor Perspectives in Medicine, 2013
Neuroblastoma, the most common extracranial solid tumor of childhood, is thought to originate from undifferentiated neural crest cells. Amplification of the MYC family member, MYCN, is found in ∼25% of cases and correlates with high-risk disease and poor
Weiss, William A, Huang, Miller
core   +6 more sources

An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability [PDF]

Nature Communications, 2021
To achieve the very high oncoprotein levels required to drive the malignant state cancer cells utilise the ubiquitin proteasome system to upregulate transcription factor levels.
Z. Nagy, Janith A. Seneviratne, Maxwell Kanikevich, William Chang, C. Mayoh, Pooja Venkat, Yan-Hua Du, Ci-Zhong Jiang, Alice Salib, J. Koach, Daniel R. Carter, Rituparna Mittra, Tao Liu, M. Parker, B. Cheung, G. Marshall   +15 more
semanticscholar   +2 more sources

MYCN-targeting miRNAs are predominantly downregulated during MYCN-driven neuroblastoma tumor formation [PDF]

Oncotarget, 2015
MYCN is a transcription factor that plays key roles in both normal development and cancer. In neuroblastoma, MYCN acts as a major oncogenic driver through pleiotropic effects controlled by multiple protein encoding genes as well as microRNAs (miRNAs ...
Vandesompele, Jo, Speleman, Franki, De Preter, Katleen, Mestdagh, PieterGE310020045679478020000565190000-0001-7821-9684F86E58A6-F0ED-11E1-A9DE-61C894A0A6B4, Van Peer, GertUGent002004437807802000680147972012922374040D108A-F0EE-11E1-A9DE-61C894A0A6B4, Schulte, Johannes H, Mestdagh, Pieter, Marshall, Glenn M, De Preter, KatleenGE310019977437938010014650600000-0002-7726-5096F60746CC-F0ED-11E1-A9DE-61C894A0A6B4, Van Peer, Gert, Beckers, AnneleenUGent002005499753802000743397979878893662052B5C6A-F0EE-11E1-A9DE-61C894A0A6B4, Carter, Daniel R, Speleman, FrankiGE318010006240890000-0002-6628-8559F4388FA4-F0ED-11E1-A9DE-61C894A0A6B4, Althoff, Kristina, Beckers, Anneleen, Cheung, Belamy B, Vandesompele, JoGE318010011883090000-0001-6274-0184F5540E9A-F0ED-11E1-A9DE-61C894A0A6B4, Peer, GV, Schulte, JH, Mets, E, Althoff, K, Vandesompele, J, Marshall, GM, Carter, DR, Speleman, F, Mestdagh, P, Beckers, A, Cheung, BB ; https://orcid.org/, De Preter, KD   +28 more
core   +8 more sources

MYCN and Metabolic Reprogramming in Neuroblastoma

Cancers, 2022
Simple Summary Metabolic reprogramming has a central role in the initiation and progression of cancer, including high-risk neuroblastoma, a deadly childhood malignant tumor of the sympathetic nervous system. This rewiring of cellular metabolism increases
M. Bansal, Anamika Gupta, Han-Fei Ding
semanticscholar   +3 more sources

MYCN upregulates the transsulfuration pathway to suppress the ferroptotic vulnerability in MYCN-amplified neuroblastoma [PDF]

Cell Stress, 2022
Ferroptosis is an iron-dependent, oxidative form of cell death that is countered mainly by glutathione peroxidase 4 (GPX4) and the production of glutathione (GSH), which is formed from cysteine.
K. Floros, Ayesha T. Chawla, Mia O. Johnson-Berro, Rishabh Khatri, Angeliki M. Stamatouli, S. Boikos, M. Dozmorov, L. Cowart, A. Faber   +8 more
semanticscholar   +4 more sources

KAP1 stabilizes MYCN mRNA and promotes neuroblastoma tumorigenicity by protecting the RNA m6A reader YTHDC1 protein degradation

Journal of Experimental & Clinical Cancer Research
Background Neuroblastoma (NB) patients with amplified MYCN often face a grim prognosis and are resistant to existing therapies, yet MYCN protein is considered undruggable.
Yi Yang, Yingwen Zhang, Guoyu Chen, Bowen Sun, Fei Luo, Yijin Gao, Haizhong Feng, Yanxin Li   +7 more
doaj   +2 more sources

Targeting MYCN in Pediatric and Adult Cancers

Frontiers in Oncology, 2021
The deregulation of the MYC family of oncogenes, including c-MYC, MYCN and MYCL occurs in many types of cancers, and is frequently associated with a poor prognosis.
Zhihui Liu, Samuel S. Chen, Saki Clarke, Veronica Veschi, Carol J. Thiele   +4 more
doaj   +2 more sources

Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors [PDF]

Oncotarget, 2016
MYC oncoproteins deliver a potent oncogenic stimulus in several human cancers, making them major targets for drug development, but efforts to deliver clinically practical therapeutics have not yet been realized.
Raynaud, Florence, Chesler, Louis, Chesler, L, Gustafson, CW, Clarke, PA, Burke, Rosemary, Robinson, Simon P, Chanthery, Y, Pearson, A, Gustafson, Clay W, Tucker, E, Workman, Paul, Maira, Michel, Workman, P, Robinson, SP, Maira, M, Tucker, Elizabeth, Li, Xiaodun, Burke, R, Barker, K, Vaughan, L, Jamin, Y, Clarke, Paul A, Renshaw, J, Jamin, Yann, Weiss, William A, Barker, Karen, Raynaud, F, Weiss, WA, Vaughan, Lynsey, Chanthery, Yvan, Renshaw, Jane, Li, X, Pearson, Andrew   +33 more
core   +6 more sources

A MYCN-driven de-differentiation profile identifies a subgroup of aggressive retinoblastoma

Communications Biology
Retinoblastoma are childhood eye tumors arising from retinal precursor cells. Two distinct retinoblastoma subtypes with different clinical behavior have been described based on gene expression and methylation profiling.
Tatsiana Ryl, Elena Afanasyeva, Till Hartmann, Melanie Schwermer, Markus Schneider, Christopher Schröder, Maren Wagemanns, Arthur Bister, Deniz Kanber, Laura Steenpass, Kathrin Schramm, Barbara Jones, David T. W. Jones, Eva Biewald, Kathy Astrahantseff, Helmut Hanenberg, Sven Rahmann, Dietmar R. Lohmann, Alexander Schramm, Petra Ketteler   +19 more
doaj   +2 more sources